

Table SI. Patient demographics and baseline characteristics

Parameter	PBO n = 361	ETN n = 740	IXE Q4W n = 733	IXE Q2W n = 736
Age, years, mean (SD)	45.9 (12.1)	45.5 (13.3)	45.3 (13.1)	45.1 (13.2)
Male, n (%)	257 (71.2)	505 (68.2)	502 (68.5)	475 (64.5)
Race, n (%)				
White	325 (90.0)	682 (92.7)	675 (92.6)	691 (94.0)
African American	18 (5.0)	23 (3.1)	20 (2.7)	10 (1.4)
Asian	13 (3.6)	19 (2.6)	22 (3.0)	24 (3.3)
Native Hawaiian or Other	1 (0.3)	2 (0.3)	2 (0.3)	4 (0.5)
American Indian or Alaska Native	3 (0.8)	4 (0.5)	6 (0.8)	3 (0.4)
Multiple	1 (0.3)	6 (0.8)	4 (0.5)	3 (0.4)
Duration of psoriasis (years), mean (SD)	18.62 (12.6)	18.50 (12.1)	18.49 (12.6)	18.06 (12.2)
Previous systemic therapy, yes, n (%)	209 (57.9)	447 (60.4)	456 (62.2)	440 (59.8)
Prior biologic therapy, yes, n (%)	76 (21.1)	136 (18.4)	143 (19.5)	142 (19.3)
PASI Score, mean (SD)	20.86 (8.4)	19.90 (7.5)	20.62 (7.6)	20.07 (7.8)
Itch NRS Score, mean (SD)	6.4 (2.7)	6.4 (2.6)	6.4 (2.6)	6.5 (2.6)
DLQI Score, mean (SD)	12.8 (7.1)	12.0 (7.0)	11.8 (6.8)	12.4 (6.9)
Joint Pain VAS, mean (SD)	52.9 (25.8)	47.9 (30.9)	50.0 (28.3)	48.2 (28.4)

DLQI: Dermatology Life Quality Index; ETN: etanercept; IXE Q2W: ixekizumab 80 mg once every 2 weeks; IXE Q4W: ixekizumab 80 mg once every 4 weeks; PASI: Psoriasis Area and Severity Index; PBO: placebo; SD: standard deviation; VAS: visual analogue scale.